Ptc Therapeutics (PTCT) Current Deferred Revenue (2012 - 2026)

Ptc Therapeutics' Current Deferred Revenue history runs 15 years deep, the most recent figure standing at $498000.0 for Q1 2026.

• On a quarterly basis, Current Deferred Revenue fell 96.12% year-over-year to $498000.0 in Q1 2026; TTM through Mar 2026 was $498000.0, a 96.12% decrease from a year earlier, with the FY2025 full-year figure at $2.0 million, down 62.94% from the prior year.
• Current Deferred Revenue retreated to $498000.0 in Q1 2026 per PTCT's latest filing, from $2.0 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $12.8 million in Q1 2025 and bottomed at $200000.0 in Q1 2023.
• The 5-year median for Current Deferred Revenue is $1.5 million (2022), against an average of $3.6 million.
• Across the five-year window, Current Deferred Revenue jumped 587.27% in 2024 and slumped 96.12% in 2026, its largest moves.
• Year by year, Current Deferred Revenue stood at $1.4 million in 2022, then tumbled by 40.71% to $801000.0 in 2023, then soared by 587.27% to $5.5 million in 2024, then tumbled by 62.94% to $2.0 million in 2025, then slumped by 75.59% to $498000.0 in 2026.
• Per Business Quant, the three latest PTCT Current Deferred Revenue figures stand at $498000.0 (Q1 2026), $2.0 million (Q4 2025), and $1.7 million (Q3 2025).